S&P 500   4,283.85 (+0.24%)
DOW   33,573.28 (+0.03%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
S&P 500   4,283.85 (+0.24%)
DOW   33,573.28 (+0.03%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
S&P 500   4,283.85 (+0.24%)
DOW   33,573.28 (+0.03%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
S&P 500   4,283.85 (+0.24%)
DOW   33,573.28 (+0.03%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
NYSE:AXR

AMREP (AXR) Stock Forecast, Price & News

$15.14
-0.01 (-0.07%)
(As of 06/6/2023 ET)
Compare
Today's Range
$14.94
$15.14
50-Day Range
$13.59
$15.25
52-Week Range
$10.26
$16.72
Volume
2,845 shs
Average Volume
6,692 shs
Market Capitalization
$79.49 million
P/E Ratio
2.72
Dividend Yield
N/A
Price Target
N/A

AMREP MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.58% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.25mentions of AMREP in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$27,300 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Finance Sector

622nd out of 862 stocks

Subdividers & Developers, Not Elsewhere Classified Industry

1st out of 3 stocks


AXR stock logo

About AMREP (NYSE:AXR) Stock

AMREP Corp. engages in the real estate businesses. It focuses on the entitlement, development and sale of land for residential, commercial, and industrial uses. The firm operates through the following segments: Land Development, Homebuilding, and Corporate. The company was founded in 1961 and is headquartered in Havertown, PA.

Receive AXR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AMREP and its competitors with MarketBeat's FREE daily newsletter.

AXR Stock News Headlines

AMREP (NYSE:AXR) Now Covered by StockNews.com
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
AMREP (NYSE:AXR) Research Coverage Started at StockNews.com
AMREP (NYSE:AXR) Now Covered by Analysts at StockNews.com
AMREP (NYSE:AXR) Coverage Initiated at StockNews.com
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
AMREP Reports Third Quarter Fiscal 2023 Results
2 Real Estate Stocks to Sell ASAP and 1 to Buy
AMREP Reports Second Quarter Fiscal 2023 Results
AMREP Reports First Quarter Fiscal 2023 Results
See More Headlines

AXR Price History

AXR Company Calendar

Last Earnings
3/13/2023
Today
6/06/2023
Next Earnings (Estimated)
7/20/2023
Fiscal Year End
4/30/2024

Industry, Sector and Symbol

Industry
Subdividers & developers, not elsewhere classified
Sub-Industry
N/A
Sector
Finance
CIK
6207
Employees
19
Year Founded
N/A

Profitability

Net Income
$15.86 million
Pretax Margin
35.83%

Debt

Sales & Book Value

Annual Sales
$62.48 million
Cash Flow
$2.23 per share
Book Value
$11.34 per share

Miscellaneous

Free Float
3,321,000
Market Cap
$79.49 million
Optionable
Not Optionable
Beta
0.97

Key Executives

  • Christopher V. Vitale
    President, CEO, Secretary & Director
  • Adrienne M. Uleau
    Vice President-Finance & Accounting













AXR Stock - Frequently Asked Questions

How have AXR shares performed in 2023?

AMREP's stock was trading at $11.55 at the beginning of 2023. Since then, AXR shares have increased by 31.1% and is now trading at $15.14.
View the best growth stocks for 2023 here
.

Are investors shorting AMREP?

AMREP saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 16,500 shares, a decline of 5.7% from the April 30th total of 17,500 shares. Based on an average trading volume of 7,000 shares, the days-to-cover ratio is currently 2.4 days. Currently, 0.6% of the company's stock are sold short.
View AMREP's Short Interest
.

When is AMREP's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 20th 2023.
View our AXR earnings forecast
.

How were AMREP's earnings last quarter?

AMREP Co. (NYSE:AXR) announced its earnings results on Monday, March, 13th. The business services provider reported $3.12 EPS for the quarter. The business services provider had revenue of $9.12 million for the quarter. AMREP had a net margin of 51.42% and a trailing twelve-month return on equity of 35.19%.

What is Theodore J. Gaasche's approval rating as AMREP's CEO?

2 employees have rated AMREP Chief Executive Officer Theodore J. Gaasche on Glassdoor.com. Theodore J. Gaasche has an approval rating of 100% among the company's employees. This puts Theodore J. Gaasche in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What is AMREP's stock symbol?

AMREP trades on the New York Stock Exchange (NYSE) under the ticker symbol "AXR."

Who are AMREP's major shareholders?

AMREP's stock is owned by many different retail and institutional investors. Top institutional shareholders include Dimensional Fund Advisors LP (3.06%), Renaissance Technologies LLC (2.28%) and Cerity Partners LLC (2.25%). Insiders that own company stock include Edward B Cloues II and Nick G Karabots.
View institutional ownership trends
.

How do I buy shares of AMREP?

Shares of AXR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AMREP's stock price today?

One share of AXR stock can currently be purchased for approximately $15.14.

How much money does AMREP make?

AMREP (NYSE:AXR) has a market capitalization of $79.49 million and generates $62.48 million in revenue each year. The business services provider earns $15.86 million in net income (profit) each year or $5.57 on an earnings per share basis.

How can I contact AMREP?

AMREP's mailing address is 620 WEST GERMANTOWN PIKE SUITE 175, PLYMOUTH MEETING PA, 19462. The official website for the company is www.amrepcorp.com. The business services provider can be reached via phone at (610) 487-0905 or via fax at 609-716-8255.

This page (NYSE:AXR) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -